This global licensing agreement is an extension of the existing partnership between the two parties.
original agreement was implemented in August 2019, in which Aedes aegym obtained exclusive development and commercialization rights in Japan for all cognitive function tests developed by Cogstate, including CBB.
the two companies plan to continue to advance the development of CBB globally, using CBB as a tool for individuals to self-assess brain function, to help people choose healthy lifestyles and take preventive measures in their daily lives, and as a medical device to assist medical practitioners in making clinical diagnostic decisions.
CBB is a digital tool developed by Cogstate that performs cognitive function self-testing and uses four tests to assess mental motor function, attention, learning memory, and working memory.
Cogstate's technology is easy to use, available in more than 70 languages and has been scientifically validated by more than 600 peer-reviewed publications.
COGTSTATE technology has been widely used in clinical trials, including a number of trials conducted by Wesser.
In the United States, Europe, Australia, New Zealand and Canada, CBB is used as a "CognigramTM" medical device and has obtained market authorization from regulators in those regions to provide medical personnel with informational results to support clinical testing and assist in the diagnosis of MCI and dementia.
is currently building a dementia patient platform called "Easyit", which centers on the brain performance self-test tools "NouKNOW" and "Easyit App" (an app designed to promote health action through visualization of brain and physical health data).
is investigating the possibility of developing medical devices in Japan that combine CBB technology.
note: There are deletions in the original text